Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease, Mild Cognitive Impairment

In brief

This pilot clinical trial will examine the effects of intranasal insulin aspart on cognition, daily function, blood and cerebral spinal fluid markers of Alzheimer's disease, and amyloid deposition in the brain. Participants will be randomly assigned to receive insulin aspart or placebo during a 12-week treatment period.

Key facts

Study ID
NCT02462161
Run by
Wake Forest University Health Sciences
People needed
24
Starts
2015-03-20
Expected to finish
2019-04-16
Last updated by the study team
2025-07-28

Who can join

Age: 50 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.